There is a high medical need for an interferon-free , all-oral , short-duration therapy for hepatitis C virus ( HCV ) that is highly effective across diverse patient populations , including patients with cirrhosis or previous null response to pegylated interferon ( peginterferon ) plus ribavirin ( PR-null responders ) .